On January 4, 2018 Shire plc (LSE: SHP, NASDAQ: SHPG) reported that Flemming Ornskov, M.D., M.P.H., Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in in San Francisco, California on Monday, January 8th, 2018, at 10:30 AM Pacific Standard Time (18:30 GMT) (Press release, Shire, JAN 4, 2018, View Source [SID1234522894]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation and the questions & answers session will be available on Shire’s Investor website at View Source Subsequently, a replay of the webcast will be available on this same website for approximately 90 days.

On January 4, 2018 Dynavax Technologies Corporation (NASDAQ:DVAX) reported that Eddie Gray, Dynavax’s chief executive officer, will present at the J.P. Morgan 36th Annual Healthcare Conference next week in San Francisco, CA (Press release, Dynavax Technologies, JAN 4, 2018, View Source [SID1234522868]). The presentation will be webcast live and will occur on Thursday, January 11, 2018 at 7:30 a.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and replayed versions of the webcast will be available by visiting the "Investors" section of the Dynavax website at www.dynavax.com.

On January 4, 2018 Cue Biopharma, Inc., (NASDAQ: CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, reported that it will be featured as a presenting company at the upcoming 10th Annual Biotech Showcase Conference on January 9, 2018, in San Francisco, CA (Press release, Cue Biopharma, JAN 4, 2018, View Source [SID1234522915]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Date: Tuesday, January 9, 2018

Time: 11:15 am PT

Duration: 15 minutes

Location: Franciscan Room B at the Ballroom Level of the Hilton San Francisco Union Square

Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma, will provide an overview of the Company’s technology platform and overall development strategy and give updates on key programs, including anticipated development milestones.

On January 4, 2018 Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases, reported that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday January 10, 2018 at 2:30 p.m. PT (Press release, Myovant Sciences, JAN 4, 2018, http://investors.myovant.com/news-releases/2018/01-04-2018-133105307 [SID1234522891]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will be webcast live and may be accessed via the Events page under the Investors and Media section of Myovant’s website at www.myovant.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 30 days following the conference.

On January 4, 2018 Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, reported that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview, including 2018 objectives, at the 36th Annual J.P. Morgan Healthcare Conference (Press release, Syros Pharmaceuticals, JAN 4, 2018, View Source [SID1234522895]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

36th Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 11
Time: 10:30 a.m. PST (1:30 p.m. EST)
Location: Westin St. Francis Hotel, 335 Powell St., San Francisco, CA

The presentation will be followed by a question and answer session.

A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.